BioPharma Dive March 18, 2025
The startup is developing a rare disease treatment it says can address limitations of therapies from Alnylam and Novo Nordisk.
Arbor Biotechnologies on Tuesday announced a new $74 million fundraise that comes as many of its peers in genetic medicine struggle to secure venture investment.
The Series C round led by Arch Venture Partners and TCGX will help Arbor advanced its lead program into clinical testing. Arbor is developing the gene editing therapy, dubbed ABO-101, for a rare kidney condition called primary hyperoxaluria type 1. A Phase 1/2 trial enrolling about two dozen volunteers is listed in a federal database, but hasn’t yet begun recruiting patients.
Primary hyperoxaluria type 1, or PH1, occurs when the body produces too much of...
Today's Sponsors
Today's Sponsor